CONtrol TNF, CONquer Psoriasis
"A breakthrough in psoriasis management, uniting scientific rigor and clinical excellence for long-term relief"
A Globally Patented Breakthrough in Psoriasis Care
Tinefcon® is the world’s first oral TNF-α & IL-12/23 down-regulator, filling the treatment gap, powered by the clinically proven phytoactive extract of Sphaeranthus indicus.
Breakthrough in the Management of Psoriasis
As a dermatologist, you confront the complexities of psoriasis daily. This chronic, immune-mediated inflammatory disease, characterized by erythematous, scaly plaques, presents a significant clinical challenge. The underlying pathogenesis, driven by T-cell activation and subsequent keratinocyte hyperproliferation, demands a therapeutic strategy that is both targeted and comprehensive.
The impact on a patient’s Quality of Life (QoL) is profound, extending far beyond the physical symptoms. In India, with an estimated 14 million individuals affected, the need for effective, reliable, and accessible treatment options has never been more critical.
Introducing Tinefcon—a new paradigm in psoriasis management. Our integrated system of oral and topical therapies is engineered to provide superior clinical outcomes, offering you and your patients a new standard of care.
Tinefcon: Globally Patented, originally Researched in India
In the management of psoriasis, dermatologists seek therapies that are both highly effective and possess a favorable safety profile for long-term patient care. Tinefcon emerges as a breakthrough in this landscape, offering a novel solution developed from a proprietary, patented extract of Sphaeranthus indicus—a phytopharmaceutical with a respected history in traditional Indian medicine. Our research successfully bridges this ancient wisdom with modern science, transforming a traditional source into a standardized, phytoactive, clinical-grade therapy that delivers consistent and reliable results.
This unique, phytoactive-based therapy is not merely a phytopharmaceutical remedy; it is a product of rigorous scientific validation. Tinefcon is specifically engineered to target the underlying immunological drivers of psoriatic inflammation, offering a precise approach to disease management. Backed by extensive clinical data and patented for its unique mechanism, it provides an evidence-based treatment you can trust to restore skin health and improve the quality of life for your patients.
Backed by Robust Clinical Trials across more than 30 sites in India
Clinically Proven: Validated in a landmark study with 500+ patients across 30+ sites in India
Decade of R&D: A product of over 10 years of world-class research by Piramal Enterprises
Patented Science: Recognized for its unique anti-inflammatory and immunomodulatory action
Tablet
Phase II
Phase IV
Cream
Phase II
Globally Patented & originally researched in India and backed by a decade of clinical research on 500+ Patients across India.
Patients treated with Tinefcon® can look forward to meaningful improvements not only in their skin but also in their overall quality of life. By addressing psoriasis at its root, Tinefcon® offers both rapid symptom relief and sustained disease control.
Expected Patient Benefits
Fast Relief – Noticeable reduction in itching, scaling, and redness within just 3 months
Proven Efficacy – Demonstrated improvement in PASI scores with visibly reduced plaque thickness
Restored Skin Health – Supports smoother skin and promotes long-term disease management
Why is Tinefcon the Best Choice?
